The Searle Company Limited
Manufacturer Holds a DRAP Drug Manufacturing Licence (DML) for its products. Source: DRAP.
Public pharmaceutical manufacturer · Karachi · Pakistan
Publicly listed Pakistan pharmaceutical company manufacturing and marketing medicines and consumer-health products with domestic and international operations.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Public pharmaceutical manufacturer
- Address
- One IBL Centre, 2nd Floor, Plot #1, Block 7 & 8, D.M.C.H.S, Tipu Sultan Road, Off Shahrah-e-Faisal, Karachi, Pakistan
- Website
- searlecompany.com ↗
- Phone
- +92 21 37170200-201
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Aforbs | Amlodipine | 5 mg | Tablet | 20's | 110438 | PKR 202.64 | PKR 10.13/tablet | 7% below median |
| Aforbs | Amlodipine | 10 mg | Tablet | 20's | 110439 | PKR 279.82 | PKR 13.99/tablet | 21% below median |
| Alcorib | Ribavirin | 400 mg | Tablet | 10’s | 047385 | PKR 185.88 | PKR 18.59/tablet | Near median |
| Alcorib | Ribavirin | 500 mg | Tablet | 10's | 047386 | PKR 874.41 | PKR 87.44/tablet | 346% above median |
| Alcorib | Ribavirin | 600 mg | Tablet | 10's | 047387 | PKR 981.04 | PKR 98.10/tablet | 301% above median |
| Aldactone | Spironolactone | 100 mg | Tablet | 10’s | 003203 | PKR 277.95 | PKR 27.80/tablet | 124% above median |
| Aldactone –A | Spironolactone | 25 mg | Tablet | 30's | 000017 | PKR 205.68 | PKR 6.86/tablet | 155% above median |
| Aldactone –A | Spironolactone | 25 mg | Tablet | 100’s | 000017 | PKR 685.60 | PKR 6.86/tablet | 155% above median |
| Anzica | Tranexamic acid | 250 mg/5 mL | Injection | 10's | 053343 | PKR 490.53 | PKR 49.05/vial/unit | 28% below median |
| Astroz | Anastrozole | 1 mg | Tablet | 30's | 093683 | PKR 10,716.88 | PKR 357.23/tablet | Near median |
| Athenil | Simvastatin | 10 mg | Tablet | 10's | 028394 | PKR 351.11 | PKR 35.11/tablet | 21% above median |
| Athenil | Simvastatin | 20 mg | Tablet | 10's | 028395 | PKR 619.61 | PKR 61.96/tablet | 36% above median |
| Athenil | Simvastatin | 40 mg | Tablet | 10's | 033370 | PKR 857.12 | PKR 85.71/tablet | 19% above median |
| Atrium Injetion | Atracurium besylate | 10 mg/mL | Injection | 5's | 053342 | PKR 1,413.37 | PKR 282.67/vial/unit | No comparator |
| Azitron | Azithromycin | 250 mg | Tablet | 6's | 054512 | PKR 324.33 | PKR 54.06/tablet | 15% above median |
| Benza | Albendazole | 200 mg | Tablet | 2's | 054508 | PKR 36.25 | PKR 18.13/tablet | 16% above median |
| Beslol | Bisoprolol fumarate | 2.5 mg | Tablet | 14's | 076191 | PKR 66.21 | PKR 4.73/tablet | 12% above median |
| Beslol | Bisoprolol fumarate | 10 mg | Tablet | 20's | 076192 | PKR 479.88 | PKR 23.99/tablet | 8% above median |
| Beslol | Bisoprolol fumarate | 5 mg | Tablet | 20's | 076542 | PKR 258.16 | PKR 12.91/tablet | 9% above median |
| Biozolin | Cefazolin | 250 mg | Injection | 1's | 013501 | PKR 108.82 | PKR 108.82/vial/unit | 46% above median |
| Biozolin | Cefazolin | 500 mg | Injection | 1's | 013502 | PKR 157.20 | PKR 157.20/vial/unit | 30% above median |
| Biozolin | Cefazolin | 1 g | Injection | 1's | 013503 | PKR 289.81 | PKR 289.81/vial/unit | 42% above median |
| Calan | Verapamil | 120 mg | Tablet | 20's | 007276 | PKR 155.53 | PKR 7.78/tablet | No comparator |
| Calan | Verapamil | 40 mg | Tablet | 50's | 007309 | PKR 196.90 | PKR 3.94/tablet | 15% above median |
| Calan | Verapamil | 80 mg | Tablet | 50’s | 007310 | PKR 286.80 | PKR 5.74/tablet | 10% below median |
| Calan | Verapamil | 240 mg | Tablet | 10’s | 009773 | PKR 0.00 | — | No comparator |
| Calan | Verapamil | 5 mg/2 mL | Injection | 5's | 091256 | PKR 190.26 | PKR 38.05/vial/unit | Near median |
| Calan | Verapamil | 5 mg/2 mL | Injection | 1's | 091256 | PKR 36.89 | PKR 36.89/vial/unit | Near median |
| Cizumab | Bevacizumab | 100 mg/4 mL | Injection | 1's | 105573 | PKR 33,268.91 | PKR 33,268.91/vial/unit | 19% below median |
| Cizumab | Bevacizumab | 400 mg/16 mL | Concentrate for solution for infusion | 1's | 105574 | PKR 132,267.99 | PKR 132,267.99/vial/unit | 22% below median |
| Cizumab | Bevacizumab | 400 mg/16 mL | Injection | 1's | 105574 | PKR 132,267.99 | PKR 132,267.99/vial/unit | 19% below median |
| Cizumab EU | Bevacizumab | 100 mg/4 mL (25 mg/mL) | Concentrate for infusion | 1's | 120492 | PKR 25,715.63 | PKR 25,715.63/vial/unit | Near median |
| Cizumab EU | Bevacizumab | 100 mg/4 mL | Solution for infusion | 1's | 120492 | PKR 25,715.63 | PKR 25,715.63/vial/unit | No comparator |
| Cizumab EU | Bevacizumab | 400 mg/16 mL | Solution for infusion | 1's | 120493 | PKR 102,238.25 | PKR 102,238.25/vial/unit | No comparator |
| Clariza | Clarithromycin | 250 mg | Tablet | 10’s | 054513 | PKR 506.06 | PKR 50.61/tablet | 6% above median |
| Clariza | Clarithromycin | 500 mg | Tablet | 10’s | 054514 | PKR 826.13 | PKR 82.61/tablet | Near median |
| Clariza XL | Clarithromycin | 500 mg | Prolonged-release tablet | 5’s | 069062 | PKR 427.52 | PKR 85.50/tablet | 7% below median |
| Clariza XL | Clarithromycin | 500 mg | Prolonged-release tablet | 1's | 069062 | PKR 92.95 | PKR 92.95/tablet | Near median |
| Co-Telnip | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 28's | 103256 | PKR 1,256.19 | PKR 44.86/tablet | Near median |
| Co-Telnip | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 28's | 103257 | PKR 2,367.34 | PKR 84.55/tablet | Near median |
| Co-Telnip | Telmisartan + Hydrochlorothiazide | 80 mg + 25 mg | Tablet | 28's | 103258 | PKR 2,377.99 | PKR 84.93/tablet | Near median |
| Co-Telnip + | Telmisartan + Hydrochlorothiazide | 40 mg + 12.5 mg | Tablet | 14's | 103256 | PKR 661.15 | PKR 47.23/tablet | 8% above median |
| Co-Telnip + | Telmisartan + Hydrochlorothiazide | 80 mg + 12.5 mg | Tablet | 14's | 103257 | PKR 1,247.65 | PKR 89.12/tablet | 9% above median |
| Co-Telnip + | Telmisartan + Hydrochlorothiazide | 80 mg + 25 mg | Tablet | 14's | 103258 | PKR 1,258.32 | PKR 89.88/tablet | 6% above median |
| Cobcid | Ascorbic acid | 500 mg | Chewable tablet | 40's | 101334 | PKR 80.20 | PKR 2.01/tablet | 51% above median |
| Dactovi | Daclatasvir | 30 mg | Tablet | 28's | 084779 | PKR 5,612.87 | PKR 200.46/tablet | Near median |
| Dactovi | Daclatasvir | 60 mg | Tablet | 28's | 084780 | PKR 9,183.98 | PKR 328.00/tablet | Near median |
| Dalimab | Adalimumab | 40 mg/0.8 mL | Prefilled syringe injection | 1's | 115136 | PKR 63,329.85 | PKR 63,329.85/syringe | No comparator |
| Defera | Deferasirox | 250 mg | Tablet | 28's | 100421 | PKR 9,994.34 | PKR 356.94/tablet | 19% above median |
| Defera | Deferasirox | 250 mg | Tablet | 1's | 100421 | PKR 355.48 | PKR 355.48/tablet | 18% above median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.